14102 studies
BACKGROUND: Emotional reactions to treatment could affect treatment adherence and treatment outcomes, and it is therefore important to assess the emotional impact of treatment and consider this impact in clinical decision-making. The Emotional Impact…
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, is increasingly used worldwide for weight loss and glycaemic control but is associated with gastrointestinal side effects. We her…
Introduction This study aims to evaluate the risk of residual gastric content (RGC) among patients taking semaglutide/tirzepatide undergoing an esophagogastroduodenoscopy (EGD). Methods A retrospective observational study was conducted from 2024 to 2…
Obesity is the most prevalent condition in high-income nations, primarily associated with increased risk of diabetes, cardiovascular disease (CVD), hypertension, and hyperlipidemia. Lifestyle modifications are a key determinant in non-pharmacological…
BACKGROUND: This meta-analysis aimed to evaluate the relation between tirzepatide exposure and the risk of adverse cardiovascular or renal events in participants with type 2 diabetes mellitus (T2DM) or obesity. METHODS: A comprehensive search was con…
. Obesity as a chronic disease: the key role of new therapies. The global prevalence of overweight and obesity has risen dramatically, with obesity now recognized as a chronic, progressive, and multifactorial disease linked to major health complicati…
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes mellitus. We report a case of acute mesenteric ischemia in a patient following treatmen…
Obesity management is complex; medications must be used in conjunction with behavioural changes and monitoring by health professionals. Injectable drugs for weight management include glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. liraglutide…
BACKGROUND: Tirzepatide (Mounjaro) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist increasingly prescribed for type 2 diabetes and obesity due to its efficacy in weight loss and glycae…
BACKGROUND: Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertai…
Type 2 diabetes mellitus (T2D) affects over 460 million people worldwide and profoundly diminishes their quality of life. Its onset is driven by obesity, sedentary behavior, and genetic predisposition, leading to insulin resistance, progressive beta-…
PURPOSE OF REVIEW: This review summarizes emerging evidence on the use of the dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide in improving obstructive sleep apnea (OSA) outcome…
PURPOSE: This study evaluated the effect of Tirzepatide on metabolic profiles, kidney function, and gut microbiota composition in mice with diabetic kidney disease (DKD) and clarify the relationship between gut microbiota alterations and the renoprot…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among plastic surgery patients for obesity and overweight. Agents such as dulaglutide, liraglutide, semaglutide, and tirzepatide differ in pharmacology and dosing, dire…
Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in adults with cystic fibrosis (CF). Traditional management relied on insulin therapy to counter the rise in glucose related to a carbohydrate-rich diet, which was previously reco…